Almac Group Joins Science Based Targets Initiative
Union adds to company’s goal of reaching net zero emissions by 2045.
Almac Group, a contract development and manufacturing organization (CDMO), announced it has officially joined the Science Based Targets Initiative (SBTi), which advocates for the best practices in science-based target settings. The company credits this move as the latest step taken with the objective of reaching net zero emissions by 2045.
The collaboration, which is headed by CDP, the United Nations Global Compact, the World Resources Institute (WRI), and the Worldwide Fund for Nature (WWF), is one of multiple steps Almac Group has taken to reach net zero. Other efforts include the expansion of accreditations with the International Standard Organization (ISO), accepted as the gold standard in health, safety, and environmental activity.
“Developing science-based targets for the reduction of greenhouse gas emissions is a crucial next step and demonstrates the commitment to our environmental responsibilities at Almac,” said Niall Harkin, executive director, Almac Group. “At Almac, we see transparency and alignment to internationally recognized standards as essential in demonstrating our commitment to making a measurable and positive impact on our planet.Signing up to SBTi, coupled with our latest ISO certifications represent an essential part of Almac’s plan to reach net-zero by 2045 and we are proud to mark these milestones in our progress.”
Reference: Almac Group signs up to Science Based Targets initiative. (2023, July 4).
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
